Results 181 to 190 of about 1,086,858 (267)

Essential Updates 2024–2025: Surgical Strategy for Esophageal Cancer Toward a New Paradigm in the Era of Immunotherapy and Personalization

open access: yesAnnals of Gastroenterological Surgery, EarlyView.
This review summarizes key advances from 2024 to 2025 that are reshaping esophageal cancer surgery toward a strategy‐oriented, personalized paradigm through the integration of immunotherapy, population aging, and intelligent technologies. Adjuvant nivolumab after neoadjuvant chemoradiotherapy remains the only perioperative approach with durable benefit,
Shuichiro Oya   +2 more
wiley   +1 more source

Long‐Term Outcomes After Stoma Creation in Crohn's Disease: A Retrospective Cohort Study of 422 Patients

open access: yesAnnals of Gastroenterological Surgery, EarlyView.
ABSTRACT Aim Stoma creation is often required in Crohn's disease (CD), most commonly because of progressive anorectal disease. As stoma closure strongly influences long‐term quality of life and surgical decision‐making, this study evaluated the indications and long‐term outcomes of stoma creation in patients with CD.
Kentaro Nagano   +9 more
wiley   +1 more source

Extent of Lymph Node Dissection for cStage I Siewert Type I/II Cancers Based on Lymph Node Metastasis Risk Stratification

open access: yesAnnals of Gastroenterological Surgery, EarlyView.
ABSTRACT Aim The optimal surgical strategy and extent of lymph node (LN) dissection for clinical Stage I (cStage I) adenocarcinoma of the esophagogastric junction (AEG) remain controversial. This study aimed to evaluate surgical outcomes and clarify the prevalence and distribution of LN metastasis according to tumor characteristics in cStage I Siewert ...
Masayoshi Terayama   +9 more
wiley   +1 more source

The role of artificial intelligence in postoperative clinical decision-making for pancreatic cancer: a pilot study. [PDF]

open access: yesFront Surg
Yigman S   +8 more
europepmc   +1 more source

Advancing Clinical Research

open access: yes
Advanced Science, EarlyView.
wiley   +1 more source

Potential Survival Benefit of Neoadjuvant Docetaxel, Cisplatin and 5‐Fluorouracil Therapy in Patients With Esophageal Squamous Cell Carcinoma With Multiple Lymph Node Metastases: A Single‐Institute Propensity Score Analysis

open access: yesAnnals of Gastroenterological Surgery, EarlyView.
Although neoadjuvant chemotherapy with fluorouracil, cisplatin, and docetaxel (NAC‐DCF) is the current standard neoadjuvant regimen for esophageal squamous cell carcinoma, its substantial toxicity underscores the need to identify patients who derive the greatest benefit.
Eiji Higaki   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy